MOTS-c: A Mitochondrial-Derived Peptide Under Investigation for Metabolic Research

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to MOTS-c. MOTS-c is not FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Your mitochondria do more than generate energy. They produce their own signaling molecules, encoded not in the nuclear genome but in the small circular genome that mitochondria carry from an ancient bacterial ancestor. One of those signals, a 16-amino-acid peptide called MOTS-c, appears to travel from the mitochondria to the nucleus during metabolic stress and to function as something researchers have called an exercise mimetic: a molecule that recapitulates certain metabolic effects of physical activity at the cellular level. That finding, first published in 2015, launched a wave of research and considerable interest in injectable peptide supplementation. Whether the interest has outrun the evidence is a question worth taking seriously.

Here is what MOTS-c is, what researchers have found so far, what remains unknown, and what the regulatory picture looks like as of April 2026.

Key Takeaways

• Regulatory Status: Not FDA-approved for any indication. As of April 2026, MOTS-c has no FDA bulk drug substance category classification. It is not legally marketed for human therapeutic use in the United States. As of the 2024 WADA Prohibited List, MOTS-c is banned at all times under Section S4.4 (Metabolic Modulators — AMPK activators).
• Research Stage: Primarily preclinical (mouse and rat models); limited human observational data on endogenous MOTS-c levels with age, exercise, and metabolic state. No completed, published human efficacy trials as of April 2026.
• Availability: MOTS-c is not legally marketed for human therapeutic use. Superpower Health does not prescribe, sell, or facilitate access to MOTS-c. Products sold online as research chemicals are not regulated for quality, purity, or sterility.
• Prescribing information: View compound reference data (PubChem CID 121231475)
• How it works (proposed): A 16-amino-acid mitochondrial-derived peptide that activates AMPK through folate-cycle pathway inhibition, promotes GLUT4 translocation, and translocates to the nucleus under metabolic stress to regulate antioxidant response element (ARE)-containing genes.
• What the research shows: Exercise induces an approximately 12-fold increase in skeletal-muscle MOTS-c and a 1.6-fold increase in circulation in humans, per Reynolds and colleagues in a 2021 paper in Nature Communications. Preclinical injection studies show improved insulin sensitivity and physical capacity in mouse models. No human efficacy RCTs have been published.

Where MOTS-c Comes From and How It Works

Discovery and origin

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within a short open reading frame nested inside the 12S ribosomal RNA gene of the mitochondrial genome. It was identified in 2015 by Lee, Kim, Cohen, and colleagues at the University of Southern California in a landmark paper published in Cell Metabolism. The discovery was significant for two reasons: the mitochondrial genome encodes functional peptides with systemic biological activity, and MOTS-c appeared to mediate the metabolic effects of exercise in skeletal muscle at the cellular level. The 16-amino-acid peptide belongs to a broader family of mitochondrial-derived peptides (MDPs) that also includes humanin and the small humanin-like peptides (SHLPs 1 through 6), described in a 2013 review by Lee, Yen, and Cohen in Trends in Endocrinology and Metabolism that introduced the MDP concept, and in a 2022 review by Miller, Kim, Kumagai, Yen, and Cohen in the Journal of Clinical Investigation that identified eight MDPs and characterized their declining expression with age.

Proposed mechanisms: AMPK activation and the folate cycle

The foundational mechanism proposed in the Lee et al. 2015 Cell Metabolism paper is that MOTS-c activates AMP-activated protein kinase (AMPK) through a pathway distinct from the canonical AMP/ATP ratio mechanism. Specifically, the study showed MOTS-c inhibits the folate cycle, an intermediate metabolic pathway required for de novo purine synthesis, leading to accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) — a known AMPK activator. This is described as AICAR-independent AMPK activation in the sense that the upstream trigger is folate-cycle inhibition rather than direct AICAR supplementation, though AICAR itself mediates the downstream AMPK signaling. AMPK activation in skeletal muscle promotes GLUT4 translocation to the cell surface, which increases glucose uptake independently of insulin. The 2016 review by Lee, Kim, and Cohen in Free Radical Biology and Medicine synthesized this mechanism accessibly and remains the primary mechanistic reference from the discovery laboratory. Both the mechanism and the downstream effects have been characterized in cell lines and mouse models; human confirmation of the same pathway has not been published.

Retrograde mito-to-nuclear signaling

A 2018 study by Kim, Son, Benayoun, and Lee published in Cell Metabolism extended the mechanistic picture substantially. The study showed that MOTS-c, which is produced in mitochondria, translocates from the mitochondria to the nucleus within 30 minutes of metabolic stress — induced by glucose restriction, serum deprivation, or oxidative stress in cell culture. Once in the nucleus, MOTS-c directly regulates antioxidant response element (ARE)-containing genes, including targets of NRF2-linked stress-response pathways. This established MOTS-c as a retrograde mito-to-nuclear signaling molecule, not simply an extracellular circulating peptide. The implication is that the biological activity of endogenous MOTS-c is partly intracellular and context-dependent, responding to metabolic stress in a way that injectable MOTS-c may not fully replicate. This mechanistic complexity is underappreciated in online discussions of the compound.

What the Research Shows — and What It Cannot Confirm

Insulin sensitivity and metabolic health in animal models

The 2015 Lee et al. foundational paper in Cell Metabolism reported that MOTS-c injections in C57BL/6 mice (5 mg/kg/day intraperitoneally for 7 days, n = 6–8 per group) improved insulin sensitivity on euglycemic clamp, and that 0.5 mg/kg/day for 8 weeks in CD-1 mice fed a 60% high-fat diet (n = 10 per group) attenuated diet-induced obesity and restored glucose tolerance relative to vehicle controls, with statistical significance reported at p < 0.05 to p < 0.001 across metabolic endpoints. These are small preclinical cohorts in rodent models; the translation to humans has not been demonstrated. A 2019 study by Kim, Miller, Mehta, Wan, Arpawong, Yen, and Cohen published in Physiological Reports examined metabolic pathway changes in obese mice receiving MOTS-c and found reductions in sphingolipid, monoacylglycerol, and dicarboxylate metabolism — lipid and organic acid pathways that are dysregulated in type 2 diabetes models. The 2022 review by Mohtashami, Singh, Salimiaghdam, Kenney, and colleagues, published in the International Journal of Molecular Sciences, provided a comprehensive summary of MOTS-c in human aging and age-related diseases including diabetes, obesity, cardiovascular disease, neurodegeneration, and osteoporosis, drawing on the preclinical literature. These findings are consistently positive in animal models. They have not been replicated in controlled human trials.

Exercise physiology: the most important translational data

The most translationally significant MOTS-c paper is a 2021 study by Reynolds, Lai, Woodhead, Lu, and colleagues published in Nature Communications. The study enrolled 10 young male subjects who completed an acute bout of stationary cycling with blood and skeletal-muscle biopsy sampling pre- and post-exercise, and found that acute exercise induced an approximately 12-fold increase in MOTS-c mRNA in skeletal muscle (p = 0.0098) and an approximately 1.6-fold increase in circulating MOTS-c (p = 0.0011–0.0021). The small, all-male cohort limits generalizability. These are observational measurements of endogenous peptide dynamics — not a trial of injectable MOTS-c in humans. The same paper included mouse experiments using MOTS-c at 5 and 15 mg/kg/day (acute 2-week daily dosing) and 15 mg/kg three times weekly for the late-life intermittent protocol beginning at 23.5 months of age, reporting improved treadmill performance in old mice (p = 0.000002), increased grip strength (p = 0.000078), and reduced body weight (p = 0.0013), with a lifespan trend that did not reach overall significance (p = 0.23). A 2022 rodent study by Hyatt published in Physiological Reports reported that 4 to 8 weeks of voluntary running increased skeletal-muscle MOTS-c 1.5 to 5 fold, and that a single MOTS-c injection in untrained mice increased running time by 12% and running distance by 15%. A 2022 review by Yoon, Lee, Kwon, and Kim in Diabetes and Metabolism Journal framed MOTS-c within the mitohormesis framework, noting its role in exercise-induced metabolic adaptation including adipose thermogenesis. A 2021 review by Woodhead and Merry in BBA General Subjects covered MOTS-c, humanin, and SHLPs across acute and chronic exercise paradigms in humans and rodents. The distinction between endogenous exercise-induced MOTS-c dynamics and the pharmacological injection of exogenous MOTS-c is a critical gap in the literature; the two are not equivalent.

MOTS-c levels, aging, and metabolic state: a more complicated picture

The narrative that MOTS-c simply declines with age — and that supplementation therefore restores lost function — is more complicated than online summaries suggest. A 2020 cross-sectional study by D'Souza, Woodhead, Hedges, Cohen, Merry, and colleagues published in Aging (Albany NY) measured MOTS-c in young, middle-aged, and older men and found circulating MOTS-c declined with age, consistent with the predicted narrative. However, skeletal-muscle MOTS-c was approximately 1.5-fold higher in older men than in young men, which the authors attributed to the fast-to-slow fiber type transition that occurs with aging. This is not a decline; it is an adaptive upregulation in response to the metabolic demands of aging muscle. A 2021 human cohort study by Sequeira, Woodhead, and colleagues published in Biochimica et Biophysica Acta — General Subjects measured plasma MOTS-c and SHLP2 in 125 Chinese participants (91 men, 34 women) plus an additional 34 European Caucasian women without diabetes, with MRI/S quantification of visceral, pancreatic, and liver fat; android fat had a greater effect on raising plasma MOTS-c and SHLP2 than whole-body fat, and after correction for total body fat mass liver fat positively associated with plasma MOTS-c — meaning MOTS-c was higher, not lower, in individuals with more metabolic stress. This is consistent with the retrograde stress-response role identified by Kim and colleagues in 2018: MOTS-c may rise as an adaptive compensatory signal in metabolically stressed tissue. A 2021 study by Kumagai, Coelho, Wan, Mehta, Yen, Fuku, Maeda, Cohen, and Kim published in the American Journal of Physiology — Endocrinology and Metabolism reported that plasma MOTS-c is inversely related to myostatin in humans and that MOTS-c treatment in obese mice reduced myostatin through a CK2-PTEN-mTORC2-AKT-FOXO1 signaling cascade. Taken together, these human observational findings suggest that the relationship between MOTS-c levels and metabolic health is not simply linear or unidirectional. Simple interpretations — more MOTS-c equals better metabolic health — are not supported by the data as a whole.

Bone, cardiac, and other preclinical findings

Preclinical research has extended into areas beyond metabolism. A 2016 study by Ming and colleagues published in Biochemical and Biophysical Research Communications reported that MOTS-c at 5 mg/kg/day for 12 weeks in ovariectomized female C57BL mice attenuated bone loss on micro-CT assessment, with mechanism attributed to increased phosphorylated AMPK and inhibition of RANKL-driven osteoclastogenesis; pharmacological AMPK inhibition partially abrogated the effect. The rodent ovariectomy model is a standard but imperfect surrogate for human post-menopausal bone loss, and no human data exist. A 2018 study by Hu and Chen published in the European Review for Medical and Pharmacological Sciences reported improvements in osteoporosis models involving osteogenic differentiation of bone marrow mesenchymal stem cells through a TGF-beta/Smad signaling pathway. A 2022 study by Zhong, Peng, Hu, Zhang, and Shen published in the Journal of Cellular and Molecular Medicine reported that subcutaneous MOTS-c delivered by osmotic pump in a transverse aortic constriction (TAC) pressure-overload model (n = 5–6 mice per group; 6 for echocardiography) attenuated TAC-induced cardiac dysfunction, preserved left ventricular ejection fraction (p < 0.05 to p < 0.01 across timepoints), reduced inflammatory signalling, and activated the AMPK pathway. The small per-group cohort and short-duration rodent model limit translational inference. These findings extend the mechanistic interest in MOTS-c but remain in the preclinical category. None have been followed by human trials.

The K14Q variant and centenarian biology

A genetically and biologically interesting detail in the MOTS-c literature is the K14Q variant — an Asian-specific mitochondrial DNA polymorphism (m.1382A>C, rs111033358) that produces a lysine-to-glutamine substitution at position 14 of the peptide. A 2021 study by Zempo, Kim, Fuku, and colleagues published in Aging (Albany NY) pooled data from three Japanese cohorts (J-MICC, MEC, and TMM, n = 27,527) and found that men — but not women — carrying the C-allele had a higher prevalence of type 2 diabetes, with the risk concentrated in the lowest-physical-activity tertile (a gene-by-behavior interaction). In high-fat-fed male mice, native MOTS-c injection reduced body weight and improved glucose tolerance, while K14Q-MOTS-c did not, and in vitro K14Q-MOTS-c showed diminished insulin-sensitizing activity. A 2018 review by Mendelsohn and Larrick in Rejuvenation Research discussed MDPs as aging regulators in broader context. These are observational human-genetics and preclinical mechanistic findings; they do not establish that injectable MOTS-c supplementation recreates the metabolic phenotype of the A-allele or produces longevity outcomes in humans.

MOTS-c in Context: The Mitochondrial-Derived Peptide Family

MOTS-c is one of eight identified MDPs, a family that also includes humanin and SHLPs 1 through 6. The 2022 Journal of Clinical Investigation review by Miller and colleagues remains the most comprehensive overview of this class. Humanin, identified earlier than MOTS-c, has been studied for neuroprotective and metabolic effects, and its circulating levels also decline with age. SHLPs 1 through 6, identified by Cobb, Lee, Mehta, Cohen, and colleagues in a 2016 paper published in Aging (Albany NY), are encoded in the 16S rRNA region of the mitochondrial genome; SHLP2 and SHLP3 show age-related decline in circulation, and SHLP2 was demonstrated to act as both a central and peripheral insulin sensitizer in that work. The mechanistic and therapeutic interest in MOTS-c reflects a broader recognition that mitochondrial-derived peptides may constitute an endogenous system for coordinating metabolic adaptation across tissues. That recognition is scientifically valid. Whether it translates to a safe and effective exogenous therapeutic remains undemonstrated in humans.

This comparison is for scientific context only. These compounds have different molecular structures, mechanisms, and evidence bases. None are FDA-approved for human therapeutic use.

Regulatory and Legal Status

FDA classification

As of April 2026, MOTS-c is not FDA-approved for any indication. It has not been assigned a category under the FDA's 503A bulk drug substance classification system; it does not appear on the Category 1 (eligible) or Category 2 (prohibited) bulk substance lists as of this writing. This means there is no explicit FDA-approved compounding pathway for MOTS-c at this time. It is not legally marketed as a therapeutic product in the United States. Products sold as MOTS-c through online vendors operate entirely outside pharmaceutical regulatory oversight, with no quality standards, sterility requirements, or purity verification applying to those products.

WADA prohibition

For athletes, there is a separate and explicit regulatory consideration. As of the 2024 WADA Prohibited List, MOTS-c is banned at all times under Section S4.4 (Metabolic Modulators), specifically within the AMPK activator subcategory. The U.S. Anti-Doping Agency has published an athlete advisory on MOTS-c confirming this prohibition and noting that MOTS-c is not eligible for a Therapeutic Use Exemption. Athletes subject to anti-doping testing should be aware that any use of MOTS-c, including products sourced online, creates the risk of a positive test result.

What this means practically

With both of those regulatory parameters established, the practical picture is this: MOTS-c cannot be legally obtained as a pharmaceutical compound in the United States. Products marketed as injectable MOTS-c through online research-chemical vendors exist outside regulatory oversight. They carry no verifiable purity data, no sterility certification, no established dosing standards, and no safety monitoring requirements. This is not a minor caveat. Unregulated injectable peptide products have been documented to contain contaminants, incorrect concentrations, and misidentified compounds. The absence of a regulatory pathway reflects the absence of the human safety and efficacy data that would support one.

Safety: What Is and Is Not Known

Absence of clinical safety data

No peer-reviewed human safety database for MOTS-c exists. Phase 1 pharmacokinetic or safety studies in humans have been described informally, but no published, peer-reviewed human safety data was available in the literature as of April 2026. This means the side effect profile, pharmacokinetics, organ toxicity thresholds, and drug interaction potential in humans are unknown. Animal safety data from the mouse injection studies conducted by the Lee and Cohen laboratory is reassuring within the scope of those experiments, but preclinical safety data cannot be extrapolated directly to human safety conclusions.

Reported adverse signals from unregulated use

Anecdotal reports from online communities and the USADA athlete advisory note that some individuals using unregulated MOTS-c products have reported heart palpitations and increased heart rate. These reports are not peer-reviewed, the products used were not pharmaceutical-grade, and causality cannot be established from anecdotal data alone. However, the signals are consistent with the known physiological effects of AMPK activation on cardiac energy metabolism. Given the absence of formal human safety data, these reports cannot be dismissed and should be treated as a reason for caution rather than reassurance.

Who Should Not Use MOTS-c

Based on MOTS-c's proposed mechanisms and the available preclinical evidence, the following groups face elevated theoretical risk:

• Competitive athletes subject to WADA or USADA testing — MOTS-c is explicitly banned at all times under the 2024 WADA Prohibited List (S4.4) and is not eligible for a Therapeutic Use Exemption
• Individuals with pre-existing cardiac arrhythmia or structural heart disease — anecdotal reports include palpitations and increased heart rate; AMPK activation affects cardiac energy handling, and the safety margin in individuals with cardiac pathology is unknown
• Individuals with active or suspected malignancy — MOTS-c's proposed mechanisms include modulation of cellular energy metabolism, antioxidant gene regulation, and potentially myostatin suppression; the net effect on tumor biology has not been studied
• Pregnant or breastfeeding individuals — no safety data exists in these populations
• Individuals on medications that affect AMPK signaling, insulin secretion, or glucose metabolism, including metformin, insulin, or sulfonylureas — the combined metabolic effect of MOTS-c and these agents in humans is unstudied
• Anyone who would be using unregulated online-sourced products — products sold outside pharmaceutical channels carry contamination and misdosing risks that compound the unknown safety profile of the compound itself

Which Biomarkers Are Relevant if You Are Exploring Metabolic and Mitochondrial Science?

Understanding your metabolic baseline is a reasonable and genuinely informative step for anyone interested in the biology that MOTS-c research investigates. Several of the markers below directly reflect the pathways MOTS-c is proposed to affect; others are relevant for establishing organ safety context before evaluating any investigational compound.

• Fasting insulin: Measures baseline insulin secretion and is one of the most sensitive indicators of early insulin resistance before glucose levels become abnormal. MOTS-c's primary proposed action is AMPK-mediated improvement in insulin sensitivity, making this the most mechanistically direct marker to establish as a baseline. Reference ranges vary by lab and individual context; your provider will interpret your specific results.
• Fasting glucose: A standard first-line marker for glucose handling. MOTS-c's proposed GLUT4 translocation mechanism directly affects cellular glucose uptake; establishing a baseline fasting glucose provides context for interpreting any downstream metabolic changes.
• Hemoglobin A1c (HbA1c): Reflects average glucose exposure over the preceding two to three months, providing a longer time-horizon view of glucose regulation than a single fasting measurement. Particularly relevant for anyone with metabolic syndrome risk factors. A practical guide to HbA1c explains what the measurement captures and how to contextualize it.
• Triglycerides: Elevated triglycerides are a marker of impaired lipid metabolism and are tightly correlated with insulin resistance. The 2019 Kim et al. study in Physiological Reports found that MOTS-c in obese mice reduced sphingolipid and monoacylglycerol pathway activity — both relevant to triglyceride metabolism. This makes triglycerides a biologically relevant baseline marker in the MOTS-c research context.
• High-sensitivity C-reactive protein (hs-CRP): A systemic inflammatory marker. MOTS-c's ARE-linked nuclear signaling includes NRF2-mediated antioxidant response pathways that intersect with inflammatory gene regulation. Establishing a baseline hs-CRP is relevant for any metabolic health evaluation and provides context for interpreting downstream inflammatory changes.
• Lipid panel (LDL, HDL, non-HDL cholesterol, ApoB): Metabolic syndrome and insulin resistance are associated with specific lipid patterns — elevated small, dense LDL and low HDL. A baseline lipid panel provides a comprehensive picture of cardiometabolic risk and is standard in any metabolic health assessment.
• Comprehensive metabolic panel (CMP): Includes liver enzymes (AST, ALT), kidney function (creatinine, BUN), and electrolytes. Relevant for baseline organ safety assessment before evaluating any investigational compound, and for ongoing monitoring of organ function over time.
• Complete blood count (CBC): Provides a baseline hematologic picture. Useful as part of any comprehensive baseline given the absence of human safety data for MOTS-c and the theoretical cardiovascular signals noted in anecdotal reports.

When to Take This Seriously

If the underlying biology that drives interest in MOTS-c — insulin resistance, poor metabolic flexibility, declining physical capacity with age — describes a problem you are experiencing, there are established clinical pathways worth exploring first. Endocrinologists, sports medicine physicians, and primary care providers experienced in metabolic health can evaluate insulin sensitivity, glucose regulation, and cardiometabolic risk using validated testing and FDA-approved interventions. Understanding where your blood sugar and insulin sensitivity markers currently stand is the logical starting point. It answers the question of whether there is a measurable metabolic problem before any question of how to address it.

That sequence — measure first, then decide — reflects what Superpower describes as its approach to preventive health: the conviction that objective biomarker data is the foundation for every health decision, especially when the compound under consideration lacks the controlled human trial evidence that would support confident conclusions.

IMPORTANT SAFETY INFORMATION

MOTS-c is not FDA-approved for any indication and is not legally marketed for human therapeutic use in the United States. As of April 2026, MOTS-c has no FDA 503A bulk drug substance category designation and cannot be legally compounded by a licensed 503A pharmacy. Superpower Health does not prescribe, sell, compound, or facilitate access to MOTS-c. Superpower is a health technology platform; it does not prescribe or dispense medications or investigational compounds.

As of the 2024 WADA Prohibited List, MOTS-c is banned at all times under Section S4.4 (Metabolic Modulators — AMPK activators). Athletes subject to anti-doping testing should not use MOTS-c in any form. No Therapeutic Use Exemption is available for MOTS-c.

Safety: No completed human safety trials have been published. Anecdotal adverse signals include heart palpitations and increased heart rate. Long-term safety in humans is unknown. Products sold online as research chemicals are not regulated for purity, sterility, or accurate labeling.

Do not use MOTS-c if you are: a competitive athlete subject to anti-doping testing; pregnant or breastfeeding; taking medications that affect AMPK, insulin secretion, or glucose metabolism without first consulting a qualified healthcare provider; or obtaining a product from an unregulated online source.

This page does not constitute medical advice and is not a substitute for evaluation by a qualified healthcare provider. The information on this page is for educational purposes only and is not intended to diagnose, treat, or prevent any medical condition.

Additional Questions

What are the side effects of MOTS-c?

No peer-reviewed human safety data exists. Anecdotal reports from online communities and the USADA athlete advisory reference heart palpitations and increased heart rate in some individuals who have used unregulated MOTS-c products. Because these products are not pharmaceutical-grade, the contribution of contaminants versus the compound itself cannot be determined from those reports. Long-term safety in humans is entirely unknown.

Can a doctor prescribe MOTS-c?

No. MOTS-c is not FDA-approved for any indication and does not have a legal compounding pathway under 503A as of April 2026. It cannot be prescribed and dispensed through a licensed pharmacy. Any product sold as MOTS-c exists outside the regulated pharmaceutical system.

What is the difference between MOTS-c and humanin?

Both are mitochondrial-derived peptides encoded in the mitochondrial genome, but in different regions: MOTS-c is encoded in the 12S rRNA gene, while humanin is encoded in the 16S rRNA gene. Their proposed mechanisms differ as well — MOTS-c is primarily studied for metabolic and exercise-related effects through AMPK activation, while humanin has been more extensively studied for neuroprotective and cytoprotective effects. Both show age-related changes in circulating levels, and both belong to the MDP family described in the 2022 Miller et al. review in the Journal of Clinical Investigation. This comparison is for scientific context only; neither compound is FDA-approved for human therapeutic use.